𝔖 Bobbio Scriptorium
✦   LIBER   ✦

COMT inhibition in the treatment of Parkinson’s disease

✍ Scribed by H. M. Ruottinen; U. K. Rinne

Publisher
Springer
Year
1998
Tongue
English
Weight
99 KB
Volume
245
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simultaneous MAO-B and COMT inhibition i
Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with parkinson's disease
✍ Dr. Jukka Lyytinen; Seppo Kaakkola; Sirpa Ahtila; Päivi Tuomainen; Heikki Terävä 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 801 KB

## Abstract The effect of selegiline (L‐deprenyl) on plasma catecholamines, clinical response, and drug tolerability was studied in 13 patients with Parkinson's disease (PD) treated with L‐Dopa/benserazide and entacapone, a peripheral catechol‐__O__‐methyltransferase (COMT) inhibitor, in a placebo‐

Mortalin inhibition in experimental Park
Mortalin inhibition in experimental Parkinson's disease
✍ Davide Chiasserini; Alessandro Tozzi; Antonio de Iure; Michela Tantucci; Federic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 411 KB

Among heat shock proteins, mortalin has been linked to the pathogenesis of Parkinson's disease. In the present work a rat model of Parkinson's disease was used to analyze the expression of striatal proteins and, more specifically, mortalin expression. The possible involvement of mortalin in Parkinso

Treatment disparities in Parkinson's dis
Treatment disparities in Parkinson's disease
✍ Nabila Dahodwala; Ming Xie; Elizabeth Noll; Andrew Siderowf; David S. Mandell 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 1 views